The Federal Trade Commission said Thursday that Endo Pharmaceuticals violated federal antitrust laws by paying Impax Laboratories and Watson Laboratories to delay launching their approved generic versions. The latest case is the first by the commission that challenges an agreement not to market an authorized generic.

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations.
He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications.
His hobbies are tracking global financial developments and watching sports

Related Posts

As correlations spike, a Goldman Sachs report, re-iterating messages in previous analysis to a degree, points to a challenging market environment for stock picking as correlations and return dispersion concerns... read more